MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Effects of multimodal balance training supported by rhythmical auditory stimuli in people with advanced stages of Parkinson’s disease: A randomized clinical trial

    T. Capato, J. Nonnekes, N. de Vries, J. IntHout, E. Barbosa, B. Bloem (São Paulo, Brazil)

    Objective: To study the effectiveness of balance training with and without rhythmical auditory cues in people with advanced stages of PD (H&Y4). Background: Non-pharmacological interventions…
  • MDS Virtual Congress 2020

    A retrospective analysis of multicenter brain signal data recorded in Parkinson’s subjects implanted with deep brain stimulation leads

    M. Case, H. Bronte-Stewart, A. Kuhn, K. Botzel, A. Hebb, P. Starr, B. Klassen, N. Ince, Z. Blumenfeld, J. Neumann, F. Hell, S. Hanrahan, N. Swann, M. Ozturk, S. Stanslaski, S. Goetz, T. Denison, K. Bhatia, R. Raike (Fridley, MN, USA)

    Objective: To assess the prevalence and factors of detectable local field potential (LFP) signals in the subthalamic nucleus (STN) of Parkinson’s disease (PD) patients. Background:…
  • MDS Virtual Congress 2020

    Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease

    C. Christine, R. Richardson, A. Van Laar, M. Thompson, K. Herbert, C. Li, G. Liang, E. Fine, P. Larson (San Francisco, CA, USA)

    Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…
  • MDS Virtual Congress 2020

    Site investigator perspectives on exclusionary determinations of SWEDDs (Scans Without Evidence of Dopaminergic Deficit) during screening in the SURE-PD3 study

    G. Crotty, E. Macklin, A. Hung, M. Schwarzschild (Boston, MA, USA)

    Objective: To assess investigators’ level of agreement with centrally adjudicated SWEDDs based on dopamine transporter imaging (qualitatively defined) during screening of subjects whom investigators had…
  • MDS Virtual Congress 2020

    MOve To ImprovE physical activity in Parkinson’s disease (MOTIvatE): A pilot randomized clinical trial of gamification

    N. Dahodwala, M. Engeland, W. Kerr, L. Walsh, M. Patel (Philadelphia, PA, USA)

    Objective: To test the feasibility and impact of a behaviorally designed gamification intervention to improve goal-directed behavior assessed by physical activity levels in Parkinson’s disease…
  • MDS Virtual Congress 2020

    In vivo imaging of presynaptic terminal loss in early Parkinson’s disease

    A. Delva, D. Van Weehaeghe, M. Koole, K. Van Laere, W. Vandenberghe (Leuven, Belgium)

    Objective: To determine the magnitude and anatomical extent of presynaptic terminal damage in early Parkinson’s disease (PD) in vivo, we performed a PET study with…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting

    A. Ellenbogen, A. Nicholas, R. Hauser, P. Bhargava, E. Pappert, B. Navia (Farmington Hills, MI, USA)

    Objective: Analyze effect of concomitant antiemetics and dopamine agonists (DA) on nausea and vomiting (N/V) in patients receiving apomorphine sublingual film (APL-130277; APL) for on-demand…
  • MDS Virtual Congress 2020

    CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks

    A. Ellenbogen, A. Corbin, P. Zhao, D. Kegler-Ebo, H. Roberts (Bingham Farms, MI, USA)

    Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…
  • MDS Virtual Congress 2020

    Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies

    L. Elmer, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (Toledo, OH, USA)

    Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders

    A. Espay, K. Markopoulou, P. Bhargava, B. Navia (Cincinnati, OH, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…
  • « Previous Page
  • 1
  • …
  • 1123
  • 1124
  • 1125
  • 1126
  • 1127
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley